Last reviewed · How we verify
biologically active human fecal microbiota
At a glance
| Generic name | biologically active human fecal microbiota |
|---|---|
| Sponsor | Virginia O. Shaffer |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis (NA)
- Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis (PHASE1, PHASE2)
- Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis (PHASE2)
- Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC) (EARLY_PHASE1)
- Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis (PHASE1, PHASE2)
- Washed Microbiota Transplantation (WMT) for Chronic Kidney Disease (CKD) (NA)
- Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients (PHASE1)
- Fecal Microbiota Transplant (FMT) for Pouchitis (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: